Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Chen, Yizhi ^a,b   Schieppati, Arrigo ^c   Chen, Xiangmei ^a   Cai, Guangyan ^a   Zamora, Javier ^d,e   Giuliano, Giovanni A ^b   Braun, Norbert ^f,g   Perna, Annalisa ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f Department of Internal Medicine   (Germany)

^g Renal Services   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CORTICOSTEROID; CORTICOTROPIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HERBACEOUS AGENT; IMMUNOSUPPRESSIVE AGENT; MIZORIBINE; MYCOPHENOLATE MOFETIL; TACROLIMUS;

ARTICLE; CREATININE BLOOD LEVEL; DISEASE COURSE; END STAGE RENAL DISEASE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; MEMBRANOUS GLOMERULONEPHRITIS; META ANALYSIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REMISSION; SYSTEMATIC REVIEW; TRIPTERYGIUM WILFORDII; ADULT; COMPLICATION; DRUG COMBINATION; GLOMERULONEPHRITIS, MEMBRANOUS; MORTALITY; PROCEDURES; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENAL CORTEX HORMONES; ADULT; ALKYLATING AGENTS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; NEPHROTIC SYNDROME; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921989440     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004293.pub3     Document Type: Article

References (168)

1. Ahmed S, Rahman M, Alam MR, Islam S, Chowdhury MN, Chowdhury SM, et al. Methyl prednisolone plus chlorambucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy - a preliminary study. Bangladesh Renal Journal 1994;13(2): 51-4. [EMBASE: 1995085509]
2. Rahman M, Ahmed S, Alam MR, Selim SI, Chowdhury MN, Chowdhury SM, et al. Methyl prednisolone plus chlorambucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy - a preliminary study [abstract]. 10th Asian Colloquium in Nephrology; 1994, Dec 2-6; Karachi, Pakistan. 1994:66.
3. Arnadottir M, Stefansson B, Berg A. A randomized study on treatment with adrenocorticotropic hormone in idiopathic membranous nephropathy [abstract no: F-PO1112]. Journal of the American Society of Nephrology 2006;17 (Abstracts):571A. [CENTRAL: CN-00782355]
4. Austin HA, Vaughan EM, Boumpas DT, Balow JE. Randomized trial of pulse cyclophosphamide and prednisone vs. prednisone alone in idiopathic membranous nephropathy [abstract no: A0410]. Journal of the American Society of Nephrology 1996;7(9):1327. [CENTRAL: CN-00583858]
5. Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Cyclophosphamide is superior to chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency [abstract no: A0395]. Journal of the American Society of Nephrology 1997;8(Programs & Abstracts):82A. [CENTRAL: CN-00444527]
6. Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Qjm 1998;91(5):359-66. [MEDLINE: 9709470]
7. Braun N, Dietz K, Vonthein R, Erley C, Risler T. Remission and relapses in idiopathic membranous nephropathy. Description by a longitudinal multi-state Markov-model [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:34-5. [CENTRAL: CN-00509101]
8. Braun N, Erley CM, Benda N, Zauner I, Kanis R, Grupp C, et al. Therapy of membranous glomerulonephritis with nephrotic syndrome. 5 years follow-up of a prospective, randomized multi-centre study [abstract]. Nephrology Dialysis Transplantation 1995;10(6):967.
9. Braun N, Erley CM, Benda N, Zauner I, Kanis R, Grupp C, et al. Therapy of membranous glomerulonephritis with nephrotic syndrome. 5 years follow-up of a prospective, randomized multi-center study [abstract]. Journal of the American Society of Nephrology 1995;6(3):413. [CENTRAL: CN-00261096]
10. Cameron JS, Healy MJ, Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Quarterly Journal of Medicine 1990;74(2):133-56. [MEDLINE: 2189149]
11. Cameron JS,Working Party of theMRCGlomerulonephritis Registry. The MRC trial of prednisolone in membranous nephropathy. The Working Party of the MRC Glomerulonephritis Registry [abstract]. Nephrology Dialysis Transplantation 1988;3(6):844. [CENTRAL: CN-00260412]
12. Cameron JS, Working party of the UK MRC Glomerulonephritis Registry. The MRC trial of prednisolone in membranous nephropathy. The Working Party of the UK MRC Glomerulonephritis Registry [abstract]. Nephrology Dialysis Transplantation 1988;3(4): 507-8. [CENTRAL: CN-00260389]
13. Cattran D, Cardella C, Charron R, Roscoe J, Cole E, Bear R, et al. Results of a controlled trial of alternate day prednisone (ADS) in idiopathic membranous glomerulonephritis (IMGN) [abstract]. Kidney International 1985;27(3):600. [CENTRAL: CN-00550495]
14. Cattran D, Cardella C, Charron R, Roscoe J, Rance P, Cusimano M, et al. Preliminary results of controlled trial of alternate-day prednisone in idiopathic membranous glomerulonephritis [abstract]. Kidney International 1981;19 (2):388-9. [CENTRAL: CN-00644365]
15. Cattran DC, Cole E, Cardella C, Charron R, Roscoe J, Delmore T, et al. Results of a controlled trial of alternate day prednisone (P) in membranous nephropathy (IMGN) [abstract]. Kidney International 1989;35(1):208. [CENTRAL: CN-00644367]
16. Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. New England Journal of Medicine 1989;320 (4):210-5. [MEDLINE: 2643046]
17. Cattran D, Greenwood CM, Ritchie S, Bernstein K, Churchill DN, Clarke WF, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):271. [CENTRAL: CN-00483446]
18. Cattran DC. Cyclosporine in the treatment of membranous nephropathy (MGN) [abstract]. 12th International Congress of Nephrology; 1993, Jun 13-18; Jerusalem, Israel. 1993:535. [CENTRAL: CN-00602121]
19. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney International 1995;47(4):1130-5. [MEDLINE: 7783410]
20. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. Cyclosporine in patients with steroidresistant membranous nephropathy: a randomized trial. Kidney International 2001;59(4):1484-90. [MEDLINE: 11260412]
21. Cattran DC, Pohl M, Maxwell D, Appel G, Hunsicker GP, Kunis C, et al. Randomized controlled trial of cyclosporine (D) vs placebo (P) in steroid resistant, nephrotic patients (NS) with membranous nephropathy (SR-MGN) [abstract]. Journal of the American Society of Nephrology 1998;9 (Program & Abstracts):85A. [CENTRAL: CN-00444711]
22. Cattran DC, Wald R, Brenchley PE, Coupes B, for the North American Nephrotic Syndrome Group and the Genes Gender and Glomerulonephritis Group. Clinical correlates of serial urinary membrane attack complex estimates in patients with idiopathic membranous nephropathy. Clinical Nephrology 2003;60(1):7-12. [MEDLINE: 12872852]
23. Chan TM, Lin AW, Tang SC, Qian JQ, Lam MF, Ho YW, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology 2007; 12(6):576-81. [MEDLINE: 17995584]
24. Chen M, Chen J, Li X, Lu F, Xu FF, Qian JQ, et al. A randomized controlled study comparing prednisone plus tacrolimus versus prednisone plus cyclophosphamide in patients with membranous nephropathy and nephrotic syndrome [abstract no: SA-PO1086]. Journal of the American Society of Nephrology 2006;17(Abstracts):802A. [CENTRAL: CN-00782317]
25. Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. American Journal of the Medical Sciences 2010;339(3):233-8. [MEDLINE: 20220333]
26. Coggins CH, Pinn V, Glassock RR, Blades JM, Cotran R, Cohen J, et al. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. New England Journal of Medicine 1979;301(24): 1301-6. [MEDLINE: 388220]
27. Coggins CH, The Collaborative Study of the Adult Nephrotic Syndrome. The effect of short-term prednisone treatment in adult nephrotics with minimal change (MC) and membranous (M) histology [abstract]. Kidney International 1977;12(6):463. [CENTRAL: CN-00784389]
28. Laurens W, Ruggenenti P, Perna A, Vanrenterghem Y, Remuzzi G. A randomised and controlled study to assess the effect of cyclosporin in nephrotic patients with membranous nephropathy and reduced renal function (CYCLOMEN). Journal of Nephrology 1994;7(4):237-47. [EMBASE: 1994281713]
29. Pisoni R, Grinyo JM, Salvadori M, Laurens W, Garini G, Oliver YA, et al. Cyclosporine versus conservative therapy in patients with idiopathic membranous nephropathy (IMN) and deteriorating renal function: Results of the CYCLOMEN trial [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):95A. [CENTRAL: CN-00583866]
30. Donadio JV, Holley KE, Anderson CF, Taylor WF. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney International 1974;6(6): 431-9. [MEDLINE: 4613934]
31. Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. American Journal of Kidney Diseases 2008;52(4): 699-705. [MEDLINE: 18585835]
32. Dussol B, Sichez H, Burtey S, Cassuto E, Kaaraslan H, Villar E, et al. Mycophenolate mofetil (MMF) in patients with idiopathic membranous nephropathy with nephrotic syndrome: a multicenter randomized trial [abstract no: THF- DS1092]. Journal of the American Society of Nephrology 2006;17(Abstracts):566A. [CENTRAL: CN-00653744]
33. Dyadyk AI, Bagriy AE, Yarovaya NF, Dyadyk IA. Results of long-term randomised study of immunosuppressive treatment of patients with idiopathic membranous glomerulonephritis [abstract]. Nephrology Dialysis Transplantation 2001;16(6):A64. [CENTRAL: CN-00487685]
34. Falk RJ, Hogan SL, Muller KE, Jennette JC. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Annals of Internal Medicine 1992; 116(6):438-45. [MEDLINE: 1371211]
35. Branten AJ, Du Buf-Vereijken PW, Wetzels JF. Early versus late start of immunosuppressive therapy in patients with membranous nephropathy; a randomized study. [abstract no: SA-PO188]. Journal of the American Society of Nephrology 2004;15(Oct):341A. [CENTRAL: CN-00583772]
36. Branten AJ, du Buf-Vereijken PW, Wetzels JF. Defining the optimal time of treatment start in patients with membranous nephropathy: a randomized study [abstract no: SU-PO969]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts): 668A. [CENTRAL: CN-00444526]
37. Hofstra JM, Branten AJ, Wetzels FM. No benefit of early start of immunosuppressive therapy in idiopathic membranous nephropathy [abstract no: F-FC264]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):60A. [CENTRAL: CN-00747283]
38. Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrology Dialysis Transplantation 2010;25(1):129-36. [MEDLINE: 19666912]
39. Imbasciati E, Cagnoli L, Case N, Pasquali S, Di Filippo G, Limido D, et al. Controlled study of treatment of steroids and chlorambucil, in alternate months, for membranous nephropathy and focal glomerulosclerosis. Preliminary evaluation of the results [Studio controllato di un trattamento a mesi alterni di steroidi e clorambucil nella nefropatia membranosa e nella glomerulosclerosi focale. Valutazione preliminare dei risultati]. Minerva Nefrologica 1980;27(4):571-5. [MEDLINE: 7019771]
40. Ponticelli C. Treatment of membranous nephropathy (MN) [abstract]. 9th Asian Colloquium in Nephrology; 1992, May 17-21; Seoul, Korea. 1992:22-4. [CENTRAL: CN-00461530]
41. Ponticelli C. Treatment of membranous nephropathy [abstract]. 12th International Congress of Nephrology; 1993, Jun 13-18; Jerusalem, Israel. 1993:565.
42. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Grassi C, et al. Controlled trial of monthly alternated courses of steroid and chlorambucil for idiopathic membranous nephropathy. Proceedings of the European Dialysis & Transplant Association 1983;19:717-23. [MEDLINE: 6348763]
43. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. New England Journal of Medicine 1984;310(15):946-50. [MEDLINE: 6366560]
44. Ponticelli C, Zucchelli P, Locatelli F, Grassi G, Limido D, Volpini T, et al. Controlled trial of monthly alternated courses of steroid and chlorambucil in idiopathic membranous nephropathy [abstract]. Kidney International 1983;23(3):554. [CENTRAL: CN-00644373]
45. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. New England Journal of Medicine 1989;320(1):8-13. [MEDLINE: 2642605]
46. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney International 1995;48(5):1600-4. [MEDLINE: 8544420]
47. Zucchelli P, Cagnoli L, Pasquali S, Casanova S, Donini U. Clinical and morphologic evolution of idiopathic membranous nephropathy. Clinical Nephrology 1986;25(6): 282-8. [MEDLINE: 3524923]
48. Zucchelli P, Ponticelli C, Cagnoli L, Aroldi A, Beltrandi E. Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy. American Journal of Nephrology 1988;8(1):15-20. [MEDLINE: 2967032]
49. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. Journal of the American Society of Nephrology 2007;18(6):1899-904. [MEDLINE: 17494881]
50. Jha V, Kohli HS, Sud K, Gupta KL, Sakhuja V. A randomized controlled trial of steroids and cyclophosphamide in adults with idiopathic membranous nephropathy [abstract no: FC3-02]. Nephrology 2003;8(Suppl):A16.
51. Jha V, Kohli HS, Sud K, Krishan L, Joshi K, Sakhuja V. Randomized controlled trial of steroids and cyclophosphamide in adults with idiopathic membranous nephropathy [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):213A. [CENTRAL: CN-00445921]
52. Jha V, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, et al. A randomized controlled trial of steroids and cyclophosphamide in adults with idiopathic membranous nephropathy [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998, Jun 6-9; Rimini, Italy. 1998:114.
53. Jurubita R, Ismail G, Bobeica G, Rusu E, Zilisteanu D, Andronesi A, et al. Efficacy and safety of triple therapy with MMF, cyclosporine and prednisolone versus cyclosporine and prednisolone in adult patients with idiopathic membranous nephropathy and persistent heavy proteinuria [abstract]. Nephrology Dialysis Transplantation 2012;27 (Suppl 2):FP347.
54. Koshisawa S, Sato M, Narita M, Sakai O, Nakajima M. Clinical evaluation of an immunosuppressive drug, mizoribine (HE-69) on steroid-resistant nephrotic syndrome. A multicenter double-blind comparison study with placebo. Jin ToTohseki [Kidney & Dialysis] 1993;34(4): 631-50.
55. Kosmadakis G, Filiopoulos V, Smirloglou D, Skarlas P, Georgoulias C, Michail S. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy. Renal Failure 2010;32(5):566-71. [MEDLINE: 20486839]
56. Liu ZH, Li SJ, Wu Y, Zuo K, Wang B, Zeng CH, et al. Treatment of membranous nephropathy with Tripterygium wilfordii and steroid: a prospective randomized control trial. Shenzangbing Yu Touxi Shenyizhi Zazhi [Chinese Journal of Nephrology Dialysis & Transplantation] 2009;18(4):303-9.
57. Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clinical Nephrology 1992;37(5): 229-34. [MEDLINE: 1606772]
58. Naumovic R, Jovanovic D, Pavlovic S, Stosovic M, Marinkovic J, Basta-Jovanovic G. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study. Biomedicine & Pharmacotherapy 2011;65(2):105-10. [MEDLINE: 21109389]
59. Pahari DK, Das S, Dutta BN, Banerjee D. Prognosis and management of membraneous nephropathy. Journal of the Association of Physicians of India 1993;41(6):350-1. [MEDLINE: 8005970]
60. Ponticelli C. Treatment of idiopathic membranous nephropathy (IMN) [abstract]. Pakistan Society of Nephrology & Urology. 10th Asian Colloquium in Nephrology; 1994, Dec 2-6; Karachi, Pakistan. 1994:38.
61. Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. New England Journal of Medicine 1992;327(9):599-603. [MEDLINE: 1640953]
62. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. Journal of the American Society of Nephrology 1998;9(3):444-50. [MEDLINE: 9513907]
63. Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. American Journal of Kidney Diseases 2006;47 (2):233-40. [MEDLINE: 16431252]
64. Praga M, Barrio V, Juárez GF, Luño J, Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney International 2007;71(9):924-30. [MEDLINE: 17377504]
65. Reichert LJ,Huysmans FT, Assmann K, Koene RA,Wetzels JF. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Annals of Internal Medicine 1994;121(5):328-33. [MEDLINE: 8042821]
66. Reichert LJ, Koene RA, Wetzels JF. Chlorambucil but not pulse cyclophosphamide reverses the deterioration of renal function in patients with membranous glomerulonephropathy [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):285.
67. Saito T, Watanabe M, Ogahara S, Shuto H, Kataoka Y. Significance of blood concentration of cyclosporine at 2 hours after administration for the treatment of idiopathic membranous nephropathy with steroid resistant nephrotic syndrome [abstract no: SA285]. World Congress of Nephrology; 2009 May, 22-26; Milan, Italy. 2009.
68. Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrology Dialysis Transplantation 2008;23(6):1926-30. [MEDLINE: 17989103]
69. Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, et al. A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clinical & Experimental Nephrology 2004;8(2):117-26. [MEDLINE: 15235928]
70. Western Canadian Glomerulonephritis Study Group. Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. Canadian Medical Association Journal 1976;115(12): 1209-10. [MEDLINE: 793706]
71. De Jong PE. ACE inhibition versus corticosteroids in membranous nephropathy (ACIMEN). European Union biomedical and health research: the BIOMED 1 programme. Vol. 1, Amsterdam: IOS Press, 1995:606-607. [ISBN 0929-6743]
72. Stegeman CA, De Zeeuw D, De Jong PE. ACE inhibition versus corticosteroids in membranous nephropathy (ACIMEN). Journal of Nephrology 1994;7(5):294-300. [EMBASE: 1994344069]
73. Mathew TH. The treatment of idiopathic glomerulonephritis. Proceedings of the Second Asian Pacific Congress of Nephrology. 1983:164-72. Tiller D. Australian glomerulonephritis trial: membranous glomerulonephritis, mesangiocapillary glomerulonephritis [abstract]. Australian & New Zealand Journal of Medicine 1981;11(4):603. [CENTRAL: CN-00583749]
74. Tiller DJ, Clarkson AR, Mathew T, Thompson N, Row G, Lauer C, et al. A prospective randomised trial of cyclophosphamide, dipyridamole and warfarin in membranous and mesangiocapillary glomerulonephritis. In: Zurukzoglu W, Papadimitriou M, Pyrpasopoulos M, Sion M, Zamboulis C editor(s). Advances in Basic and Clinical Nephrology. 8th International Congress of Nephrology; 1981 June 7-12; Athens, Greece. Basel: Karger, 1981:345-51.
75. Xu J, Zhang W, Xu YW, Chen N. A double-blinded prospective randomised study on the efficacy of corticosteroid plus cyclophosphamide or FK506 in idiopathic membranous nephropathy patients with nephrotic syndrome [abstract]. NDT Plus 2010;3(Suppl 3): iii431. [EMBASE: 70484584]
76. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D. Induction and long-term treatment with Cyclosporin A in membranous glomerulonephritis with the nephrotic syndrome [abstract no: SA-PO1020]. Journal of the American Society of Nephrology 2005;16(Nov):780A. [CENTRAL: CN-00644271]
77. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrology Dialysis Transplantation 2006;21(11):3127-32. [MEDLINE: 16968719]
78. Ambalavanan S, Fauvel J-P, Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. Journal of the American Society of Nephrology 1996;7(2):290-8. [MEDLINE: 8785399]
79. Austin HA, Braun MJ, Howard LV, Kopp JB, Balow JE. Sirolimus therapy in idiopathic and lupus membranous nephropathy [abstract]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):561A.
80. Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. British Medical Journal 1970;3(5270):412-6. [MEDLINE: 4916790]
81. Dominguez-Gil B, Hernandez E, Segura J, Carreno A, Morales E, Herrero JC, Praga M. Immunosuppressive treatment in idiopathic membranous glomerulonephritis (MGN) with progressive renal function worsening [abstract]. Nephrology Dialysis Transplantation 1999;14(9): A155. [MEDLINE: CN-00583436]
82. Torres A, Dominguez-Gil B, Carreno A, Segura J, Gonzalez E, Ortiz M, et al. Immunosuppressive treatment in idiopathic membranous glomerulonephritis (MGN) with progressive renal function worsening [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):99A. [CENTRAL: CN-00783416]
83. Torres A, Domínguez-Gil B, Carreño A, Hernández E, Morales E, Segura J, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney International 2002;61 (1):219-27. [MEDLINE: 11786104]
84. du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy StudyGroup. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrology Dialysis Transplantation 2004;19(5):1142-8. [MEDLINE: 14993502]
85. Edefonti A, Ghio L, Bettinelli A, Paterlini G. Unconjugated hyperbilirubinemia due to cyclosporin a (CyA) administration in children with nephrotic syndrome (NS) [abstract]. Pediatric Nephrology 1987;1(4):C8. [CENTRAL: CN-00465774]
86. Edefonti A, Ghio L, Bettinelli A, Paterlini G, Giani M, Nebbia G, et al. Unconjugated hyperbilirubinemia due to ciclosporin administration in children with nephrotic syndrome. Contributions to Nephrology 1988;67:121-4. [MEDLINE: 3208520]
87. Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, et al. Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing/steroid dependant nephrotic syndrome (FR/SDNS): long term study [abstract]. 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 - Sept 4; Jerusalem, Israel. 1992:C70. [CENTRAL: CN-00483820]
88. Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, et al. Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing/steroid dependent nephrotic syndrome (FR/SDNS): long term study [abstract]. Journal of the American Society of Nephrology 1992;3(3):310. [CENTRAL: CN-00520331]
89. Ponticelli C. A multicenter controlled prospective trial with cyclosporine vs cyclophosphamide in frequent relapsers and steroid dependent patients with idiopathic nephrotic syndrome. Journal of Nephrology 1989;2(2):147-51. [EMBASE: 1991014828]
90. Ponticelli C. Ciclosporin in the treatment of idiopathic nephrotic syndrome [abstract]. 10th Asian Colloquium in Nephrology; 1994, Dec 2-6; Karachi, Pakistan. 1994:116.
91. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrology Dialysis Transplantation 1993;8 (12):1326-32. [MEDLINE: 8159300]
92. Ponticelli C, Rivolta E. Ciclosporin in minimal-change glomerulopathy and in focal segmental glomerular sclerosis. [Review] [39 refs]. American Journal of Nephrology 1990;10 (Suppl 1):105-9. [MEDLINE: 2256469]
93. Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. American Journal of Nephrology 2007;27 (3):226-31. [MEDLINE: 17389782]
94. Lagrue G, Bernard D, Bariety J, Druet P, Guenel J. Treatment with chlorambucil and azathioprine in primary glomerulonephritis. Results of a "controlled" study [Traitement par le chlorambucil et l'azathioprine dans les glomérulonéphrites primitives: Résultats d'une étude "controlée"]. Journal d Urologie et de Nephrologie 1975;81 (9):655-72. [MEDLINE: 765492]
95. Li X, Lv R, He Q, Li H, Du X, LinW, et al. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. Journal of Nephrology 2008;21(4):584-91. [MEDLINE: 18651550]
96. Majima K, Hori Y, Inoue T, Ishizaki K, Kinoshita E, Nomura G. The effects of treatment with prednisolone in patients with idiopathic membranous nephropathy [abstract]. 11th International Congress of Nephrology; 1990, Jul 15-20; Tokyo, Japan. 1990:117A. [CENTRAL: CN-00784437]
97. Michail S, Filiopoulos V, Kosmadakis G, Tentolouris N, Georgoulias C, Gobou A, et al. Comparison of three regimens in patients with idiopathic membranous nephropathy (IMN) associated with nephrotic syndrome (NS) [abstract no: SP053]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004, May 15-18; Lisbon, Portugal. 2004:34. [CENTRAL: CN-00509354
98. Anonymous. Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party. British Medical Journal 1971;2(5756):239-41. [MEDLINE: 4929367]
99. Nand N, Das R, Jaswal TS. Evaluation of efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis. Journal of the Indian Medical Association 1997;95(6):163-5, 174. [MEDLINE: 9420390]
100. Plavljanic D, Spoljar-Scukanec M, Milutinovic S. Tubular damage in patients with membranous nephropathy. The response to treatment [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998, Jun 6-9; Rimini, Italy. 1998:193. [CENTRAL: CN-00485443]
101. Polenakovic M, Grcevska L, Polenakovic H. Longterm follow-up of patients with stage II idiopathic membranous nephropathy (IMN)- good response to steroid and chlorambucil treatment [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A76. [CENTRAL: CN-00520378]
102. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney International 1993;43(6):1377-84. [MEDLINE: 8315953]
103. Rashid HU, Khanam A, Islam KM. Treatment of membranous nephropathy with prednisolone and ACEinhibitor [abstract]. ISN XIII International Congress of Nephrology; 1995, Jul 2-6; Madrid, Spain. 1995:269.
104. Gopal KA, Sahay M, Raman A, Narayen G. Ponticelli regime for membranous nephropathy - do Indians respond differently? [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):615. [CENTRAL: CN-00445523]
105. Sahay M, Anuradha, Narayen G. Ponticelli regimen for membranous nephropathy - do Indians respond differently? [abstract]. Indian Journal of Nephrology 2002;12(4):180. [CENTRAL: CN-00461642]
106. Shilov EM, Krasnova TN, Ivanov AA, Ivanova LV, Shnyakina OV, Tareyeva IE. Oral cyclophosphamide versus cyclophosphamide (CPA) pulses in membranous and mesangial GN [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998, Jun 6-9; Rimini, Italy. 1998:116. [CENTRAL: CN-00485850]
107. Sun GD, Xu ZG, Luo P, Miao LN. The effect of tacrolimus combined with small dose of hormone on idiopathic membranous nephropathy. Zhongguo Shiyong Neike Zazhi [Chinese Journal of Practical Internal Medicine] 2008;28(7): 542-545. [ChiCTR-TRC-09000539]
108. Tejani A, Suthanthiran M, Pomrantz A. A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children. Nephron 1991;59(1):96-9. [MEDLINE: 1944755]
109. Yao X, Chen H, Wang Q, Tang Z, Hu W, Yin G, et al. Cyclosporin A treatment for idiopathic membranous nephropathy. Chinese Medical Journal 2001;114(12): 1305-8. [MEDLINE: 11793859]
110. Yao XD, Li L, Tang Z, Hu WX, Ying G, Chen HP. Prospective clinical trial of Cyclosporin A in idiopathic membranous nephropathy [abstract]. 6th Asian Pacific Congress of Nephrology; 1995, Dec 5-9; Hong Kong. 1995:52. [CENTRAL: CN-00462029]
111. Appel G, Nachman P, Hogan S, Radhakrishnan J, Old C, Hebert L, et al. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (IMN): preliminary baseline and pharmacokinetic (PK)/ pharmacodynamic (PD) data [abstract no: SU-PO970]. Journal of the American Society of Nephrology 2002;13 (Program & Abstracts):668A.
112. Berg AL. Treatment with adrenocorticotropic hormone in idiopathic membranous nephropathy. http:// www.controlled-trials.com 2007.
113. Gaskin G. A national, randomised controlled trial of immunosuppressive therapy in idiopathic membranous nephropathy with declining renal function. 2004. http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx? publication?id=N0016094239 (accessed 3 April 2014).
114. Hirayama K, Koyama A. CYPMEN (CYclosporine with/without Prednisolone in MEmbranous Nephropathy) study. 2006. http://www.anzctr.org.au/ ACTRN12609000996268.aspx (accessed 3 April 2014).
115. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013;381(9868):744-51. [MEDLINE: 23312808]
116. Mathieson PW. The UK randomized controlled trial of Immunosuppression for progressive membranous nephropathy [abstract no: THOR048]. Journal of the American Society of Nephrology. 2011; Vol. 22:11A.
117. Liu Z. Tacrolimus treatment of patients with idiopathic membranous nephropathy. http://clinicaltrials.gov/ct2/ show/NCT00302523 (accessed 3 April 2014).
118. Liu Z. To compare the efficacy and safety of Tripterygium wilfordii (TW) versus valsartan in the membranous nephropathy (MN). http://clinicaltrials.gov/ct2/show/ NCT00518219 (accessed 3 April 2014).
119. Saito T. Combined therapy of prednisolone and mizoribine in membranous nephropathy with refractory nephrotic syndrome. www.who.int/trialsearch/trial.aspx?trialid= JPRN-C000000368 (accessed 3 April 2014).
120. ChiCTR-TRC-08000098. Research on integrated therapy of traditional Chinese medicine for membranous nephropathy. http://www.chictr.org/en/proj/show.aspx? proj=1290 (accessed 3 April 2014).
121. ChiCTR-TRC-11001144. A prospective randomized study on the efficacy of steroid combined with CTX or tacrolimus in IMN patients with NS. http://www.chictr.org/en/proj/ show.aspx?proj=261 (accessed 3 April 2014).
122. CTRI/2010/091/000231. Comparison of efficacy of tacrolimus versus cyclophosphamide in idiopathic membranous nephropathy. http://apps.who.int/trialsearch/ Trial.aspx?TrialID=CTRI/2010/091/000231 (accessed 3 April 2014).
123. EUCTR2007-005410-39-ES. Randomized pilot study comparing tacrolimus vs. cyclophosphamide-prednisone in idiopathic membranous nephropathy - MEMTAC [Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática - MEMTAC]. http://apps.who.int/trialsearch/ Trial.aspx?TrialID=EUCTR2007-005410-39-ES (accessed 3 April 2014).
124. JPRN-UMIN000001099. Optimal use of ciclosporin in membranous nephropathy (OCIM-NS study). http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000001321&language=E (accessed 3 April 2014).
125. JPRN-UMIN000006939. High-dose gamma-globulin therapy for nephrotic membranous nephropathy patients. http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000007975&language=E (accessed 93 April 2014).
126. NCT00805753. Dose-finding pilot study of ACTH in patients with idiopathic membranous nephropathy (MN). http://www.clinicaltrials.gov/ct2/show/NCT00805753 (accessed 3 April 2014).
127. NCT00843856. Mycophenylate mofetil and tacrolimus versus tacrolimus for the treatment of idiopathic membranous glomerulonephritis (IMG) (MTAC). http:// www.clinicaltrials.gov/ct2/show/NCT00843856 (accessed 3 April 2014).
128. NCT01093157. A dose escalation study of longacting ACTH gel in membranous nephropathy. http:// www.clinicaltrials.gov/ct2/show/NCT01093157 (accessed 3 April 2014).
129. NCT01161459. Treatment of idiopathic membranous nephropathy with Tripterygium wilfordii plus steroid vs tacrolimus plus steroid. http://www.clinicaltrials.gov/ct2/ show/NCT01161459 (accessed 3 April 2014).
130. NCT01180036. A randomized controlled trial of rituximab versus cyclosporine in the treatment of membranous nephropathy (IMN). http://www.clinicaltrials.gov/ct2/ show/NCT01180036 (accessed 3 April 2014).
131. NCT01282073. Mycophenolate mofetil in patients with progressive idiopathic membranous nephropathy (MMFPRIMER). http://www.clinicaltrials.gov/ct2/show/ NCT01282073? (accessed 3 April 2014).
132. NCT01386554. Acthar for treatment of proteinuria in membranous nephropathy patients (CHART). http:// www.clinicaltrials.gov/ct2/show/NCT01386554? (accessed 3 April 2014).
133. NCT01508468. Evaluate rituximab treatment for idiopathic membranous nephropathy (GEMRITUX). http: //www.clinicaltrials.gov/ct2/show/NCT01508468 (accessed 3 April 2014). Additional references
134. Ahuja M, Goumenos D, Shortland JR, Gerakis A, Brown CB. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy?. American Journal of Kidney Diseases 1999;34 (3):521-9. [MEDLINE: 10469864]
135. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. New England Journal of Medicine 2009;361 (1):11-21. [MEDLINE: 19571279]
136. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. Journal of the American Society of Nephrology 2011;22(8):1543-50. [MEDLINE: 21784898]
137. Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2011;2:CD002948. [DOI: 10.1002/ 14651858.CD002948.pub2]
138. Chen YZ, Gao Q, Zhao XZ, Chen XM, Zhang F, Chen J, et al. Meta-analysis of tTripterygium wilfordii hook F in the immunosuppressive treatment of IgA nephropathy. Internal Medicine 2010;49(19):2049-55. [MEDLINE: 20930429]
139. Chen YZ, Zhao XZ, Wu J, Mei CL. Combination regimen of leflunomide plus methylprednisolone in a female patient with reactive arthritis and concomitant IgA nephropathy. Chinese Medical Journal 2010;123(3):375-8. [MEDLINE: 20193265]
140. Couchoud C, Laville M, Boissel JP. Treatment of membranous nephropathy: a meta-analysis. Nephrology Dialysis Transplantation 1994;9(5):469-70. [MEDLINE: 8090324]
141. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. American Journal of Kidney Diseases 2005;46(6):1012-29. [MEDLINE: 16310567]
142. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2009;151(4):229-40, W49-51. [MEDLINE: 19687490]
143. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20): 3443-57. [MEDLINE: 16345038]
144. Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study effects in meta-analyses. The Stata Journal 2009;9(2):197-210.
145. Herrmann SM, Sethi S, Fervenza FC. Membranous nephropathy: the start of a paradigm shift. Current Opinion in Nephrology & Hypertension 2012;21(2):203-10. [MEDLINE: 22240444]
146. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
147. Hofstra JM, Wetzels JF. Alkylating agents in membranous nephropathy: efficacy proven beyond doubt. Nephrology Dialysis Transplantation 2010;25(6):1760-6. [MEDLINE: 20133280]
148. Hofstra JM, Wetzels JF. Management of patients with membranous nephropathy. Nephrology Dialysis Transplantation 2012;27(1):6-9. [MEDLINE: 21737514]
149. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. American Journal of Kidney Diseases 1995; 25(6):862-75. [MEDLINE: 7771482]
150. Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A metaanalysis of the controlled trials. Journal of the American Society of Nephrology 1995;5(8):1553-8. [MEDLINE: 7756587]
151. KDIGO. Idiopathic membranous nephropathy. Kidney International - Supplement 2012;2:186-97. [DOI: 10.1038/ kisup.2012.20]
152. Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Annals of the Rheumatic Diseases 2004;63(3):321-3. [MEDLINE: 14962970]
153. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [MEDLINE: 20332511]
154. Ponticelli C, Passerini P. Management of idiopathic membranous nephropathy. Expert Opinion on Pharmacotherapy 2010;11(13):2163-75. [MEDLINE: 20707756]
155. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360(9337):923-4. [MEDLINE: 12354476]
156. Ruggenenti P, Cravedi P, Remuzzi G. Rituximab for membranous nephropathy and immune disease: less might be enough. Nature Clinical Practice Nephrology 2009;5(2): 76-7. [MEDLINE: 19048001]
157. Srivastava RN, Vasudev AS, Bagga A. Levamisole in nephrotic syndrome. Lancet 1991;338(8777):1275. [MEDLINE: 1682671]
158. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. New England Journal of Medicine 2011;364(7):616-26. [MEDLINE: 21323541]
159. Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Annals of the Rheumatic Diseases 2006;65(3):417-8. [PUBMED: 16474039]
160. Tao X, Younger J, Fan FZ,Wang B, Lipsky PE. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis & Rheumatism 2002;46(7):1735-43. [MEDLINE: 12124856]
161. Waldman M, Austin HA 3rd. Controversies in the treatment of idiopathic membranous nephropathy. Nature Reviews Nephrology 2009;5(8):469-79. [MEDLINE: 19581908]
162. Waldman M, Austin HA 3rd. Treatment of idiopathic membranous nephropathy. Journal of the American Society of Nephrology 2012;23(10):1617-30. [MEDLINE: 22859855]
163. Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized?. Trials [Electronic Resource] 2009;10:46. [MEDLINE: 19573242]
164. Xu G, TuW, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clinical Practice 2009;111 (4):c223-8. [MEDLINE: 19287181]
165. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney International 2000;58(1): 317-24. [MEDLINE: 10886577]
166. Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, et al. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clinical Journal of The American Society of Nephrology: CJASN 2013;8(5):787-96. [MEDLINE: 23449768]
167. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. American Journal of Kidney Diseases 2004;44(3):385-401. [MEDLINE: 15332211]
168. Schieppati A, Perna A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004293.pub2]